ILC 2019: Phase 2 study reports significant reductions in alkaline phosphatase and high responder rates among individuals with primary biliary cholangitis treated with elafibranor 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A Phase…
ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression both on and off treatment with…
ILC 2019: Randomized controlled study reports favourable virological outcomes with simplified monitoring of glecaprevir/pibrentasvir treatment in chronic hepatitis C infection 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A randomized controlled study (SMART-C) designed…
Nivolumab and pembrolizumab display anti-tumour activity and adequate tolerance in ‘real-world’ studies in carcinoma ILC 2019: ‘Real-world’ studies report the activity and safety profiles of nivolumab and pembrolizumab to be in line with those observed in hepatocellular carcinoma phase II…
ILC 2019: ENCORE-PH study of emricasan in nonalcoholic steatohepatitis (NASH)-related cirrhosis and severe portal hypertension (PH) fails to meet primary endpoint, but benefits reported in individuals at high risk of decompensation 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR…
ILC 2019: Latest study suggests that integration of hepatitis B virus (HBV) DNA into the human genome is not restricted to the early phases of chronic HBV infection but also frequently occurs in individuals with hepatitis B e antigen (HBeAg)-negative…
ILC 2019: Promising results reported with givosiran in acute hepatic porphyria (AHP) and lanreotide in polycystic liver disease (PLD) associated with autosomal dominant polycystic kidney disease (ADPKD) 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…
ILC 2019: Study involving >29,000 individuals with chronic hepatitis B virus infection reports that the risk of hepatocellular carcinoma is at least one-third lower in those treated with tenofovir than in those treated with entecavir 13 April 2019, Vienna, Austria…
ILC 2019: ‘Real-world’ studies confirm the effectiveness of elbasvir/grazoprevir in people with hepatitis C (HCV) genotype 1 infection who inject and/or abuse drugs or who receive opioid substitution therapy 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY…
ILC 2019: Population-based study finds ‘critical increase’ in the burden of cirrhosis due to alcohol-related liver disease in Canada, with rising prevalence rates, high rates of late diagnosis, and poor overall survival 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…